Integrated genomic analyses in PDX model reveal a cyclin-dependent kinase inhibitor Palbociclib as a novel candidate drug for nasopharyngeal carcinoma

Integrated genomic analyses in PDX model reveal a cyclin-dependent kinase inhibitor Palbociclib as a novel candidate drug for nasopharyngeal carcinoma

Abstract Background Patient-derived xenograft (PDX) tumor model has become a new approach in identifying druggable tumor mutations, screening and evaluating personalized cancer drugs based on the mutated targets. Methods We established five nasopharyngeal carcinoma (NPC) PDXs in mouse model. Subsequ...

Full description

Bibliographic Details
Main Authors: Cheng-Lung Hsu, Kar-Wai Lui, Lang-Ming Chi, Yung-Chia Kuo, Yin-Kai Chao, Chun-Nan Yeh, Li-Yu Lee, Yenlin Huang, Tung-Liang Lin, Mei-Yuan Huang, Yi-Ru Lai, Yuan-Ming Yeh, Hsien-Chi Fan, An-Chi Lin, Yen-Jung Lu, Chia-Hsun Hsieh, Kai-Ping Chang, Ngan-Ming Tsang, Hung-Ming Wang, Alex Y. Chang, Yu-Sun Chang, Hsin-Pai Li
Format: Article
Language:English
Published: BMC 2018-09-01
Series:Journal of Experimental & Clinical Cancer Research
Subjects:
Nasopharyngeal carcinoma
Patient derived xenograft
EBV
Whole-exome sequencing
CDK4/6 inhibitor
RNA sequencing
Online Access:http://link.springer.com/article/10.1186/s13046-018-0873-5

Internet

http://link.springer.com/article/10.1186/s13046-018-0873-5

Similar Items